The $6m investment expands the group's healthcare portfolio. Boustead Singapore is expanding its healthcare technology business after investing $6m for a 60% stake in Singapore-based medical technology company UroMedTech. Through Boustead Medical Care Holdings (BMCH), the group added robotic prostate cancer diagnostics to the its healthcare portfolio. UroMedTech develops UroMaster, a robotic MRI-ultrasound fusion biopsy platform used in prostate cancer diagnosis. The company said the system has